NLS Pharmaceutics Ltd.NLS Pharmaceutics Ltd.NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd.

No trades
See on Supercharts

NLSP fundamentals

Key facts

Market capitalization

NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.


Fundamental metrics to determine fair value of the stock

No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins


Dividend yield, history and sustainability

NLSP does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company